Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on November 22, 2010. The report discloses a significant legal event concerning the Company's intellectual property rights for its product Xyrem (sodium oxybate oral solution).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal proceeding and does not contain financial performance data.
Material Changes and Events
On November 22, 2010, the Company filed a lawsuit in the United States District Court for the District of New Jersey against Roxane Laboratories, Inc. The lawsuit alleges infringement of all patents for Xyrem currently listed in the Orange Book. The action was triggered by an Abbreviated New Drug Application (ANDA) filed by Roxane seeking FDA approval to market a generic version of Xyrem prior to patent expiration.
Outlook, Risks, and Contingencies
Under the Hatch-Waxman Act, the filing of this lawsuit results in an automatic stay of FDA approval for Roxane's ANDA. This stay will remain in effect until the earlier of:
- 30 months from the Company's receipt of Roxane's Paragraph IV certification notice (October 18, 2010); or
- A District Court decision finding the identified patents invalid, unenforceable, or not infringed.
Management directs investors to the "Risk Factors" section of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, for further details on risks related to generic competition and intellectual property.
Key Facts for Investor Verification
- Verify the status of the lawsuit against Roxane Laboratories in the District of New Jersey.
- Confirm the expiration dates of the Xyrem patents listed in the Orange Book.
- Monitor the 30-month stay period, which began on October 18, 2010, to determine the earliest possible date for generic market entry.
- Review the Company's Form 10-Q filed on November 5, 2010, for detailed risk factors regarding generic competition.